Characteristics and risk factors of bone mineral density decrease in 110 patients with ankylosing spondylitis: a retrospective study
ZHANG Qiang1, DENG Weizhe1, WEI Bo1, SHEN Zhengdong2, ZHANG Hao3
1. Rheumatology and Traditional Chinese Medicine Department, the 962nd Hospital of PLA Joint Logistics Support Force , Harbin 150048, China; 2. Rheumatology and Hematology, Zhuhai Branch of Guangdong Provincial Hospital of Chinese Medicine, Zhuhai 519015, China; 3. Gastroenterology Department, Shanghai Municipal Corps Hospital of Chinese People’s Armed Police Force, Shanghai 210103,China
Abstract:Objective To analyze the clinical characteristics and risk factors of decreased bone mineral density (BMD) in patients with ankylosing spondylitis (AS). Methods A total of 110 AS patients admitted to the 962nd Hospital of PLA Joint Logistics Support Force from January 2017 to November 2023 were reviewed. DXA method was used to measure BMD and the patients were divided into normal group(T-score>-1) and decreased group(T-score≤-1).The characteristics associated with decreased BMD were analyzed using univariate analysis, and the risk factors of decreased BMD were examined using multivariate logistic regression analysis. Results The median age of AS patients in Heilongjiang Province was 25.50(21.00,32.00) years,and the median disease duration was 1.00(0.70,3.00) years, with 109 male and 1 female. BMD was normal in 74 cases, and BMD decreased in 36 cases, including low bone mass in 32 cases and osteoporosis in 4 cases. A total of 62 cases received recombinant human tumor necrosis factor receptor type Ⅱ antibody fusion protein. Univariate analysis showed that age, disease course,CRP,and ESR were associated with BMD decrease(P<0.05). Multivariate logistic analysis indicated that age(OR=1.14,95%CI:1.05~1.25),CRP(OR=1.09,95%CI:1.02~1.15),and ESR(OR=1.03,95%CI:1.00~1.07)were risk factors for BMD decrease,and recombinant human tumor necrosis factor receptor type II antibody fusion protein(OR=0.27,95%CI:0.10~0.76)was a protective factor against BMD decrease. Conclusions Age,CRP and ESR are risk factors for BMD decrease in patients with AS, while recombinant human tumor necrosis factor receptor type Ⅱ antibody fusion protein acts as a protective factor against BMD decrease.
张强, 邓伟哲, 魏博, 沈正东, 张皓. 110例强直性脊柱炎患者骨密度下降的特征及其危险因素[J]. 武警医学, 2024, 35(6): 488-492.
ZHANG Qiang, DENG Weizhe, WEI Bo, SHEN Zhengdong, ZHANG Hao. Characteristics and risk factors of bone mineral density decrease in 110 patients with ankylosing spondylitis: a retrospective study. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(6): 488-492.
Zhang M,Li X M,Wang G S,et al. The association between ankylosing spondylitis and the risk of any,hip,or vertebral fracture:a meta-analysis[J]. Medicine,2017,96(50):e8458.
[9]
Patel P, Hussain H, Fahey J. Delayed diagnosis of ankylosing spondylitis:a missed opportunity?[J]. Cureus,2019,11(9):e5723.
[10]
Mühlenfeld M,Strahl A,Bechler U,et al. Bone mineral density assessment by DXA in rheumatic patients with end-stage osteoarthritis undergoing total joint arthroplasty[J].BMC Musculoskelet Disord,2021,22(1):173.
[11]
Heijde D, Braun J, Deodhar A,et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis[J]. Rheumatology,2019,58(3):388-400.
Kim J W,Park S,Jung J Y,et al. Prevalence and factors of osteoporosis and high risk of osteoporotic fracture in patients with ankylosing spondylitis:a multicenter comparative study of bone mineral density and the fracture risk assessment tool[J]. J Clin Med,2022,11(10):2830.
Sharif K,Tsur A M,Ben-Shabat N,et al. The risk of osteoporosis in patients with ankylosing spondylitis-a large retrospective matched cohort study[J]. Med Clin(Barc),2023,160(9):373-378.
El M A,Ebo’o F B,Sadni S,et al. Is there a relation between pre-sarcopenia,sarcopenia,cachexia and osteoporosis in patients with ankylosing spondylitis?[J]. BMC Musculoskelet Disord,2016,11(17):268.
[21]
Ulu M A,Batmaz I,Dilek B,et al. Prevalence of osteoporosis and vertebral fractures and related factors in patients with ankylosing spondylitis[J]. Chin Med J,2014,127(15):2740-2747.
Ashany D,Stein E M,Goto R,et al. The effect of TNF inhibition on bone density and fracture risk and of IL-17 inhibition on radiographic progression and bone density in patients with axial spondyloarthritis:a systematic literature review[J]. Curr Rheumatol Rep,2019,21(5):20.
[26]
Nigil H N,Sriganthan J,Al G N,et al.Effect of TNF-a inhibitor treatment on bone mineral density in patientswith ankylosing spondylitis:a systematic review and meta-analysis[J].Semin Arthritis Rheum,2014,44(2):155-161.